JunD (D17G2) Rabbit mAb #5000
- WB
- IP
- IF
- F
Supporting Data
REACTIVITY | H Mk B Pg |
SENSITIVITY | Endogenous |
MW (kDa) | 38, 42 |
Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
- IP-Immunoprecipitation
- IF-Immunofluorescence
- F-Flow Cytometry
Species Cross-Reactivity Key:
- H-Human
- Mk-Monkey
- B-Bovine
- Pg-Pig
Product Information
Product Usage Information
Application | Dilution |
---|---|
Western Blotting | 1:1000 |
Immunoprecipitation | 1:200 |
Immunofluorescence (Immunocytochemistry) | 1:400 |
Flow Cytometry (Fixed/Permeabilized) | 1:200 |
Storage
Protocol
Specificity / Sensitivity
Species Reactivity:
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Pro250 of human JunD protein.
Background
JunD, along with closely related family members c-Jun and JunB, is a transcription factor that can activate or repress a wide array of target genes (1,2). JunD transcriptional activity is modulated by phosphorylation in response to cellular stress via the c-Jun N-terminal Kinase (JNK)/Stress-Activated Protein Kinase (SAPK) family of protein kinases (3,4). JunD activity can also be modulated by the MAPK pathway in response to growth factors. Its transcriptional capacity is further regulated by other binding partners that affect JunD expression levels and DNA binding capacity (reviewed in 2). All Jun proteins are capable of forming dimers with Fos-, ATF- and CREB-family transcription factors to form the AP-1 complex that differentially regulates a variety of target genes involved in cellular growth, proliferation, differentiation, and apoptosis (reviewed in 2 and 6). Unlike JunB and c-Jun, which share a high degree of homology (>95%), JunD is less conserved (~75%) at the amino acid level (1). Growing evidence suggests that JunD protein expression is regulated independently of other family members (reviewed in 2). It is thought that JunD may have functional significance beyond the typical Jun-family milieu. This is exemplified by the fact that JunD knockout mice are viable, bearing specific defects in cardiomyocyte function and bone growth, whereas their c-Jun counterparts develop significant, multi-organ defects during embryogenesis and die at E12.5 (6-9). JunD appears to specifically regulate genes involved in antioxidant response and hydrogen peroxide production and plays an important role in angiogenesis via its ability to exert transcriptional control over the VEGF gene (10). Furthermore, JunD appears to play an important roll in metabolism via modulation of IGF-I signaling pathways (11). Recent studies have shown that JunD regulates GADD45 α and γ expression in prostate cancer cells and that inhibition of JunD promotes apoptosis. Thus, JunD may be a viable therapeutic target for the treatment of prostate cancer (12).
- Berger, I. and Shaul, Y. (1991) Oncogene 6, 561-6.
- Hernandez, J.M. et al. (2008) Oncogene 27, 4757-67.
- Vinciguerra, M. et al. (2004) J Biol Chem 279, 9634-41.
- Stocco, C.O. et al. (2002) J Biol Chem 277, 3293-302.
- Eferl, R. and Wagner, E.F. (2003) Nat Rev Cancer 3, 859-68.
- Thépot, D. et al. (2000) Development 127, 143-53.
- Hilberg, F. et al. (1993) Nature 365, 179-81.
- Meixner, A. et al. (2010) Cell Death Differ 17, 1409-19.
- Hilfiker-Kleiner, D. et al. (2005) Circulation 112, 1470-7.
- Gerald, D. et al. (2004) Cell 118, 781-94.
- Laurent, G. et al. (2008) Cell Metab 7, 113-24.
- Zerbini, L.F. et al. (2011) Cell Cycle 10, 2583-91.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.